IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-49915-5.html
   My bibliography  Save this article

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Author

Listed:
  • Jacob E. Till

    (Abramson Cancer Center of the University of Pennsylvania)

  • Lee McDaniel

    (Inc.)

  • Changgee Chang

    (Indiana University School of Medicine)

  • Qi Long

    (Abramson Cancer Center of the University of Pennsylvania)

  • Shannon M. Pfeiffer

    (Parker Institute for Cancer Immunotherapy)

  • Jaclyn P. Lyman

    (Parker Institute for Cancer Immunotherapy)

  • Lacey J. Padrón

    (Parker Institute for Cancer Immunotherapy)

  • Deena M. Maurer

    (Parker Institute for Cancer Immunotherapy)

  • Jia Xin Yu

    (Parker Institute for Cancer Immunotherapy)

  • Christine N. Spencer

    (Parker Institute for Cancer Immunotherapy)

  • Pier Federico Gherardini

    (Parker Institute for Cancer Immunotherapy)

  • Diane M. Silva

    (Parker Institute for Cancer Immunotherapy)

  • Theresa M. LaVallee

    (Parker Institute for Cancer Immunotherapy)

  • Charles Abbott

    (Inc.)

  • Richard O. Chen

    (Inc.)

  • Sean M. Boyle

    (Inc.)

  • Neha Bhagwat

    (Abramson Cancer Center of the University of Pennsylvania)

  • Samuele Cannas

    (Abramson Cancer Center of the University of Pennsylvania)

  • Hersh Sagreiya

    (Abramson Cancer Center of the University of Pennsylvania)

  • Wenrui Li

    (Abramson Cancer Center of the University of Pennsylvania)

  • Stephanie S. Yee

    (Abramson Cancer Center of the University of Pennsylvania)

  • Aseel Abdalla

    (Abramson Cancer Center of the University of Pennsylvania)

  • Zhuoyang Wang

    (Abramson Cancer Center of the University of Pennsylvania)

  • Melinda Yin

    (Abramson Cancer Center of the University of Pennsylvania)

  • Dominique Ballinger

    (Abramson Cancer Center of the University of Pennsylvania)

  • Paul Wissel

    (Abramson Cancer Center of the University of Pennsylvania)

  • Jennifer Eads

    (Abramson Cancer Center of the University of Pennsylvania)

  • Thomas Karasic

    (Abramson Cancer Center of the University of Pennsylvania)

  • Charles Schneider

    (Abramson Cancer Center of the University of Pennsylvania)

  • Peter O’Dwyer

    (Abramson Cancer Center of the University of Pennsylvania)

  • Ursina Teitelbaum

    (Abramson Cancer Center of the University of Pennsylvania)

  • Kim A. Reiss

    (Abramson Cancer Center of the University of Pennsylvania)

  • Osama E. Rahma

    (Dana-Farber Cancer Institute)

  • George A. Fisher

    (Stanford University)

  • Andrew H. Ko

    (San Francisco)

  • Zev A. Wainberg

    (Los Angeles)

  • Robert A. Wolff

    (The University of Texas MD Anderson Cancer Center)

  • Eileen M. O’Reilly

    (Memorial Sloan Kettering Cancer Center)

  • Mark H. O’Hara

    (Abramson Cancer Center of the University of Pennsylvania)

  • Christopher R. Cabanski

    (Parker Institute for Cancer Immunotherapy)

  • Robert H. Vonderheide

    (Abramson Cancer Center of the University of Pennsylvania)

  • Erica L. Carpenter

    (Abramson Cancer Center of the University of Pennsylvania)

Abstract

While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here we investigate KRAS ctDNA (ctKRAS) variant-specific associations with overall and progression-free survival (OS/PFS) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for patients receiving chemoimmunotherapy (“PRINCE”, NCT03214250), and an independent cohort receiving standard of care (SOC) chemotherapy. For PRINCE, higher baseline plasma levels are associated with worse OS for ctKRAS G12D (log-rank p = 0.0010) but not G12V (p = 0.7101), even with adjustment for clinical covariates. Early, on-therapy clearance of G12D (p = 0.0002), but not G12V (p = 0.4058), strongly associates with OS for PRINCE. Similar results are obtained for the SOC cohort, and for PFS in both cohorts. These results suggest ctKRAS G12D but not G12V as a promising prognostic biomarker for mPDAC and that G12D clearance could also serve as an early biomarker of response.

Suggested Citation

  • Jacob E. Till & Lee McDaniel & Changgee Chang & Qi Long & Shannon M. Pfeiffer & Jaclyn P. Lyman & Lacey J. Padrón & Deena M. Maurer & Jia Xin Yu & Christine N. Spencer & Pier Federico Gherardini & Dia, 2024. "Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49915-5
    DOI: 10.1038/s41467-024-49915-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-49915-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-49915-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Jacob J. Chabon & Emily G. Hamilton & David M. Kurtz & Mohammad S. Esfahani & Everett J. Moding & Henning Stehr & Joseph Schroers-Martin & Barzin Y. Nabet & Binbin Chen & Aadel A. Chaudhuri & Chih Lon, 2020. "Integrating genomic features for non-invasive early lung cancer detection," Nature, Nature, vol. 580(7802), pages 245-251, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Xiao Zhou & Zhen Cheng & Mingyu Dong & Qi Liu & Weiyang Yang & Min Liu & Junzhang Tian & Weibin Cheng, 2022. "Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    2. Meng Nie & Ke Yao & Xinsheng Zhu & Na Chen & Nan Xiao & Yi Wang & Bo Peng & LiAng Yao & Peng Li & Peng Zhang & Zeping Hu, 2021. "Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
    3. Hitomi Hosoya & Mia Carleton & Kailee Tanaka & Brian Sworder & Shriya Syal & Bita Sahaf & Alisha M. Maltos & Oscar Silva & Henning Stehr & Vanna Hovanky & George Duran & Tian Zhang & Michaela Liedtke , 2025. "Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma," Nature Communications, Nature, vol. 16(1), pages 1-13, December.
    4. Jonathan C. M. Wan & Dennis Stephens & Lingqi Luo & James R. White & Caitlin M. Stewart & Benoît Rousseau & Dana W. Y. Tsui & Luis A. Diaz, 2022. "Genome-wide mutational signatures in low-coverage whole genome sequencing of cell-free DNA," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    5. Nicolette M. Fonseca & Corinne Maurice-Dror & Cameron Herberts & Wilson Tu & William Fan & Andrew J. Murtha & Catarina Kollmannsberger & Edmond M. Kwan & Karan Parekh & Elena Schönlau & Cecily Q. Bern, 2024. "Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    6. Mary L. Stackpole & Weihua Zeng & Shuo Li & Chun-Chi Liu & Yonggang Zhou & Shanshan He & Angela Yeh & Ziye Wang & Fengzhu Sun & Qingjiao Li & Zuyang Yuan & Asli Yildirim & Pin-Jung Chen & Paul Winogra, 2022. "Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    7. Tiantian Wang & Peilong Li & Qiuchen Qi & Shujun Zhang & Yan Xie & Jing Wang & Shibiao Liu & Suhong Ma & Shijun Li & Tingting Gong & Huiting Xu & Mengqiu Xiong & Guanghua Li & Chongge You & Zhaofan Lu, 2023. "A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49915-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.